A Trial In Patients With Advanced Cancer And Leukemia

Status:
Completed

Trial end date:
2016-11-22

Target enrollment:

Participant gender:

This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

Phase 1

Pfizer